Description
Why It’s Done:
This test is conducted to:
• Determine hormone receptor status (ER/PR) for the selection of hormonal therapy.
• Assess HER2 gene amplification, guiding the use of HER2-targeted treatments such as trastuzumab or pertuzumab.
• Evaluate DNA ploidy, which helps estimate tumor aggressiveness and potential treatment resistance.
• Assist in prognosis and personalized treatment decisions by combining receptor status with genetic indicators of tumor behavior.
This comprehensive profile supports a more tailored approach to breast cancer care.
Preparation:
• No special patient preparation is required for this test.
• The test is performed on formalin-fixed tissue samples obtained during a biopsy or surgical excision.
• If undergoing biopsy or surgery, your doctor may advise specific instructions such as:
o Fasting (in some surgical procedures)
o Pausing certain medications
o Arranging for someone to accompany you home
Always follow your healthcare provider’s guidance


